Xencor Reports Q3 Loss, Tops Revenue Estimates
MDWD Stock | USD 15.95 1.03 6.07% |
About 54% of Mediwound's investor base is interested to short. The analysis of overall sentiment of trading Mediwound stock suggests that many investors are impartial at this time. The current market sentiment, together with Mediwound's historical and current headlines, can help investors time the market. In addition, many technical investors use Mediwound stock news signals to limit their universe of possible portfolio assets.
Mediwound |
Xencor delivered earnings and revenue surprises of 27.55 percent and 38.41, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock
Read at zacks.com
![]() |
Mediwound Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Mediwound can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Mediwound Fundamental Analysis
We analyze Mediwound's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mediwound using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mediwound based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Mediwound is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Mediwound Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Mediwound stock to make a market-neutral strategy. Peer analysis of Mediwound could also be used in its relative valuation, which is a method of valuing Mediwound by comparing valuation metrics with similar companies.
Peers
Mediwound Related Equities
NKTX | Nkarta | 1.52 | ||||
DYAI | Dyadic International | 1.48 | ||||
AVTE | Aerovate Therapeutics | 0.80 | ||||
SWTX | SpringWorks Therapeutics | 0.17 | ||||
MRUS | Merus BV | 0.49 | ||||
CRNX | Crinetics Pharmaceuticals | 0.49 | ||||
REPL | Replimune | 0.57 | ||||
INBX | Inhibrx | 1.40 | ||||
KROS | Keros Therapeutics | 1.82 | ||||
OCUL | Ocular Therapeutix | 2.19 | ||||
MLYS | Mineralys Therapeutics, | 2.27 | ||||
SNDX | Syndax Pharmaceuticals | 2.80 | ||||
RNA | Avidity Biosciences | 2.95 | ||||
GLUE | Monte Rosa | 3.04 | ||||
VCYT | Veracyte | 3.15 | ||||
KRON | Kronos Bio | 3.49 | ||||
STRO | Sutro Biopharma | 3.90 | ||||
GBIO | Generation Bio | 6.52 | ||||
SANA | Sana Biotechnology | 7.57 | ||||
LYEL | Lyell Immunopharma | 8.47 | ||||
FHTX | Foghorn Therapeutics | 9.28 |
Complementary Tools for Mediwound Stock analysis
When running Mediwound's price analysis, check to measure Mediwound's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mediwound is operating at the current time. Most of Mediwound's value examination focuses on studying past and present price action to predict the probability of Mediwound's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mediwound's price. Additionally, you may evaluate how the addition of Mediwound to your portfolios can decrease your overall portfolio volatility.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |